Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

The heat shock protein 90 inhibitor, luminespib, has demonstrated potent preclinical activity against numerous cancers. However, clinical translation has been impeded by dose-limiting toxicities that have necessitated dosing schedules which have reduced therapeutic efficacy. As such, luminespib is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Epp-Ducharme, Brittany, Dunne, Michael, Fan, Linyu, Evans, James C., Ahmed, Lubabah, Bannigan, Pauric, Allen, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160139/
https://www.ncbi.nlm.nih.gov/pubmed/34045581
http://dx.doi.org/10.1038/s41598-021-90585-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160139/
https://www.ncbi.nlm.nih.gov/pubmed/34045581
http://dx.doi.org/10.1038/s41598-021-90585-w

Ejemplares similares